<DOC>
	<DOCNO>NCT01634555</DOCNO>
	<brief_summary>The purpose study assess effect concomitant ramucirumab ( IMC-1121B ) pharmacokinetics irinotecan metabolite SN-38 coadministered folinic acid 5-fluorouracil , participant advance malignant solid tumor resistant standard therapy standard therapy available .</brief_summary>
	<brief_title>A Study Assess Pharmacokinetics Ramucirumab ( IMC-1121B ) Combination With FOLFIRI</brief_title>
	<detailed_description />
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Ramucirumab</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<mesh_term>Folic Acid</mesh_term>
	<criteria>Has histologic cytologic documentation malignant solid tumor Has advance solid tumor resistant standard therapy standard therapy available Has resolution Grade ≤1 , per National Cancer Institute Common Terminology Criteria Adverse Events , Version 4.0 ( NCICTCAE v. 4.0 ) , clinically significant toxic effect prior chemotherapy , surgery , radiotherapy , hormonal therapy Has Eastern Cooperative Oncology Group ( ECOG ) performance status 02 Has adequate hematologic , coagulation , hepatic function Has serum creatinine ≤ 1.5 x upper limit normal ( ULN ) Urinary protein &lt; 2+ dipstick routine urinalysis ( UA ) study entry Women childbearing potential must negative serum urine pregnancy test Eligible participant reproductive potential ( sex ) agree use adequate method contraception study period 12 week last dose study medication Has receive therapeutic monoclonal antibody within last 42 day Has receive cytotoxic chemotherapy within last 21 day Has receive radiotherapy within last 14 day Are currently enrol , discontinue within last 14 day , clinical trial involve investigational product nonapproved use drug device , concurrently enrol type medical research judge scientifically medically compatible study Has history deep vein thrombosis , pulmonary embolism , significant thromboembolism last 3 month Has uncontrolled illness , include , limited uncontrolled hypertension , symptomatic congestive heart failure , unstable angina pectoris , symptomatic poorly control cardiac arrhythmia , psychiatric illness/social situation , serious uncontrolled medical disorder Has experience arterial thromboembolic event within last 6 month Has know leptomeningeal disease brain metastasis uncontrolled spinal cord compression Has ongoing active infection require parenteral antibiotic , antifungal , antiviral therapy Has know human immunodeficiency virus infection acquire immunodeficiency syndromerelated illness Has receive prior organ transplantation Has undergone major surgery within last 28 day Has serious nonhealing wound , ulcer , bone fracture within last 28 day Has elective plan major surgery perform course trial Has bowel obstruction , history presence inflammatory enteropathy extensive intestinal resection , Crohn 's disease , ulcerative colitis , chronic diarrhea Has experience Grade 3 high bleeding event within last 3 month Has know history clinical evidence Gilbert 's Syndrome , know follow genotype : uridine diphosphate glucuronosyltransferase isoform 1A1 ( UGT1A1 ) *6/*6 , UGT1A1*28/*28 , UGT1A1*6/*28 Has receive clinically relevant inhibitor inducer cytochrome P ( CYP ) 450 CYP3A4/5 CYP2C9 and/or isoenzymes within last 3 week Has cirrhosis level ChildPugh B ( bad ) , cirrhosis history hepatic encephalopathy , ascites result cirrhosis require ongoing treatment diuretic and/or paracentesis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Advanced Malignant Solid Tumors</keyword>
</DOC>